MAP3K7
MOLECULAR TARGETmitogen-activated protein kinase kinase kinase 7
MAP3K7 (mitogen-activated protein kinase kinase kinase 7) is targeted by 31 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting MAP3K7
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | alvocidib | 4.52 | 91 |
| 2 | foretinib | 4.34 | 76 |
| 3 | tozasertib | 4.33 | 75 |
| 4 | ruxolitinib | 4.23 | 68 |
| 5 | bosutinib | 4.08 | 58 |
| 6 | doramapimod | 4.06 | 57 |
| 7 | quizartinib | 3.99 | 53 |
| 8 | midostaurin | 3.85 | 46 |
| 9 | nintedanib | 3.61 | 36 |
| 10 | canertinib | 3.53 | 33 |
| 11 | bms 387032 | 3.47 | 31 |
| 12 | tae 684 | 3.43 | 30 |
| 13 | fedratinib | 3.40 | 29 |
| 14 | dovitinib | 3.09 | 21 |
| 15 | lestaurtinib | 3.04 | 20 |
| 16 | defosbarasertib | 2.89 | 17 |
| 17 | r 406 | 2.83 | 16 |
| 18 | pha 665752 | 2.71 | 14 |
| 19 | kw 2449 | 2.64 | 13 |
| 20 | ast 487 | 2.56 | 12 |
| 21 | raf 265 | 2.48 | 11 |
| 22 | motesanib | 2.48 | 11 |
| 23 | hypothemycin | 2.40 | 10 |
| 24 | su 014813 | 2.20 | 8 |
| 25 | rebastinib | 2.20 | 8 |
| 26 | tg100 115 | 2.08 | 7 |
| 27 | Sorafenib | 1.61 | 4 |
| 28 | Adenosine | 0.69 | 1 |
| 29 | Adenosine Diphosphate Adenosine 5'-(trihydrogen diphosphate). | 0.69 | 1 |
| 30 | Adenosine Triphosphate | 0.69 | 1 |
| 31 | Crizotinib | 0.69 | 1 |
About MAP3K7 as a Drug Target
MAP3K7 (mitogen-activated protein kinase kinase kinase 7) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 31 compounds with documented MAP3K7 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
MAP3K7 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.